Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Sarcoma Clinical Trials

105 recruiting trials for Sarcoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
105
Total Trials
105
Recruiting Now
6
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGPhase 1NCT05130255

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step...

Sponsor: Y-mAbs TherapeuticsEnrolling: 608 locations
RECRUITINGPhase 2NCT07192068

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an...

Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the...

Sponsor: UNICANCEREnrolling: 1054 locations
RECRUITINGPhase 1NCT06771219

SLV-154 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when...

Sponsor: Solve TherapeuticsEnrolling: 709 locations
RECRUITINGPhase 1NCT07118176

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the...

Sponsor: Jonsson Comprehensive Cancer CenterEnrolling: 301 location
RECRUITINGNCT04986748

Using QPOP to Predict Treatment for Sarcomas and Melanomas

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples....

Sponsor: National Cancer Centre, SingaporeEnrolling: 1001 location
RECRUITINGPhase 1NCT06910657

IDOV-Immune for Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not...

Sponsor: ViroMissile, Inc.Enrolling: 786 locations
RECRUITINGNCT05840575

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such...

Sponsor: Rigshospitalet, DenmarkEnrolling: 1001 location
RECRUITINGNCT07129317

Pediatric Radiation Therapy Registry

The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 50002 locations
RECRUITINGPhase 1NCT06644755

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

Sponsor: Daiichi SankyoEnrolling: 1507 locations
RECRUITINGPhase 2NCT06503146

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET...

Sponsor: National Cancer Institute (NCI)Enrolling: 3201 location
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGPhase 1 / Phase 2NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation...

Sponsor: Perspective TherapeuticsEnrolling: 1127 locations
RECRUITINGPhase 2NCT03548428

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

Up to 50% of soft tissue sarcoma (STS) patients will develop metastases in the course of their disease. Cytotoxic therapy is a standard treatment in this setting but yields...

Sponsor: Centre Antoine LacassagneEnrolling: 10317 locations
RECRUITINGNCT03300830

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders...

Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical...

Sponsor: National Cancer Institute (NCI)Enrolling: 2801 location
RECRUITINGPhase 1NCT07194044

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 1517 locations
RECRUITINGNCT05539677

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 10001 location
RECRUITINGPhase 1 / Phase 2NCT06541262

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An...

Sponsor: Milton S. Hershey Medical CenterEnrolling: 10420 locations
RECRUITINGNCT04758325

The Sarcoma Biology and Outcome Project

SarcBOP - An interdisciplinary and translational registry SarcBOP aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research....

Sponsor: Prof. Dr. Richard F SchlenkEnrolling: 30001 location
RECRUITINGPhase 3NCT05597917

tTF-NGR Randomized Study - STS

In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy...

Sponsor: Universität MünsterEnrolling: 1269 locations
RECRUITINGNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international...

Sponsor: Sanford HealthEnrolling: 200002 locations
RECRUITINGPhase 2NCT06534762

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical...

Sponsor: Zhejiang Provincial People's HospitalEnrolling: 2601 location
RECRUITINGNCT06962072

Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma

The goal of this study is to assess body image, health-related quality of life (QoL), and functioning (gait function, joint function, and walking ability) in patients after...

Sponsor: Amsterdam UMCEnrolling: 1501 location
RECRUITINGNCT04621201

Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the...

Sponsor: Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'AnnaEnrolling: 12010 locations
RECRUITINGPhase 2NCT01804634

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 603 locations
RECRUITINGPhase 2NCT06650514

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered...

This is an open-label, unicentric, single-arm Phase 2 pilot study to serve as a proof-of-concept of OMO-103 safety and activity in patients with advanced high-grade osteosarcoma....

Sponsor: Vall d'Hebron Institute of OncologyEnrolling: 101 location
RECRUITINGNCT05779670

Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery

The objective of this study is to describe adherence to a personalised home exercise program in patients undergoing resection and reconstruction of lower limb for bone tumor and...

Sponsor: Istituto Ortopedico RizzoliEnrolling: 501 location
RECRUITINGNCT06789666

Digital Art Therapy for Young Cancer Survivors

This is a single-site, single-arm, interventional study assessing the feasibility of the ARTCan Therapy Application (App) and whether it is an acceptable means of administering...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 151 location
RECRUITINGPhase 2NCT04605770

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Soft tissue sarcoma (STS) is rare malignancy of mesodermal origin, representing less than 1% of all malignant neoplasms. They are a group of diseases encompassing diverse...

Sponsor: Yonsei UniversityEnrolling: 1641 location
RECRUITINGPhase 2NCT06684327

Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare...

The goal of this clinical trial is to learn if albumin-paclitaxel, ifosfamide and cisplatin (Nab-TIP) works to treat advanced rare tumors including PAGET's disease of scrotum with...

Sponsor: Fudan UniversityEnrolling: 1001 location
RECRUITINGPhase 1NCT06441331

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric...

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted...

Sponsor: ITM Solucin GmbHEnrolling: 205 locations
RECRUITINGNCT07054944

Tumor-Lymph Node Mapping

The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with...

Sponsor: University of RochesterEnrolling: 101 location
RECRUITINGNCT06111612

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

This study is a multicenter, single-arm, prospective phase II clinical trial that evaluates the efficacy and safety of an intensive conditioning regimen with thiotepa combined...

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEnrolling: 501 location
RECRUITINGPhase 3NCT06345729

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung...

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 60020 locations
RECRUITINGPhase 1NCT04999761

AB122 Platform Study

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each...

Sponsor: Taiho Pharmaceutical Co., Ltd.Enrolling: 9179 locations
RECRUITINGNCT07432932

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with...

Sponsor: Royal Marsden NHS Foundation TrustEnrolling: 8001 location
RECRUITINGPhase 2NCT05830123

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label,...

Sponsor: Hansoh BioMedical R&D CompanyEnrolling: 17011 locations
RECRUITINGPhase 2NCT06736613

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 507 locations
RECRUITINGPhase 2NCT07516925

A Study of Ivonescimab in People With Leiomyosarcoma

The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 207 locations
RECRUITINGNCT06029218

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy...

Sponsor: Centre Antoine LacassagneEnrolling: 1061 location
RECRUITINGPhase 2NCT07548177

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced...

This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in...

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Enrolling: 3315 locations
RECRUITINGNCT03099681

An Observational Study on Epithelioid Sarcoma

Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)

Sponsor: Italian Sarcoma GroupEnrolling: 10011 locations
RECRUITINGPhase 2NCT06074692

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body...

Sponsor: Ruijin HospitalEnrolling: 861 location
RECRUITINGPhase 2NCT06637007

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.

Sponsor: Shanxi Province Cancer HospitalEnrolling: 301 location
RECRUITINGPhase 1NCT06641908

Anti-GD2 ADC M3554 in Advanced Solid Tumors

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue...

Sponsor: EMD Serono Research & Development Institute, Inc.Enrolling: 5211 locations
RECRUITINGPhase 1NCT07052383

Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study...

Sponsor: Tcelltech Inc.Enrolling: 151 location
RECRUITINGNCT06062927

Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma

In this study, a new post-processing image technology - radiomics is used to screen out parameters of CT and MRI images, which could effectively evaluate the efficacy and...

Sponsor: Peking Union Medical College HospitalEnrolling: 601 location
RECRUITINGNCT02792270

Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

This study is being conducted to decrease the rate of surgical wound complications. The investigators are studying the effects that caloric restriction has on decreasing the rate...

Sponsor: Massachusetts General HospitalEnrolling: 321 location
RECRUITINGPhase 2NCT04072042

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A\>G...

Sponsor: Ruijin HospitalEnrolling: 301 location
RECRUITINGPhase 2NCT05950594

IVIM & OLINK in Sarcoma

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling...

Sponsor: University Health Network, TorontoEnrolling: 1451 location

Showing 50 of 105 trials.Search all Sarcoma trials

Frequently Asked Questions

There are currently 105 clinical trials for Sarcoma, with 105 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Sarcoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 6 Phase 3 trials for Sarcoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.